亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Improved Immunization Strategy Using Recombinant BCG Vaccines

技術優勢: 1. The use of a booster protein augments the immunoprotective effects of BCG, the most widely administered TB vaccine.2. Billions of people have already been vaccinated with BCG, and approximately 100 million newborns and infants are vaccinated annually. Thus use of the booster can be easily integrated into current vaccination protocols.3. The booster protein is a member of a group of proteins that have been shown to be immunoprotective against M. tuberculosis.4. The booster proteins have been shown to be abundantly expressed in rapidly- growing recombinant nonpathogenic bacteria and have been purified in large amounts from cultures of such recombinant bacteria.

技術應用: The booster can be used to augment immunity against M. tuberculosis and other mycobacteria (e.g. M. avium, a cause of pneumonia in immunocompromised patients such as AIDS patients, and M. leprae, the agent of leprosy). The vaccine is administered via injection (intradermally, subcutaneously, etc.)

詳細技術說明: Researchers at UCLA have developed an improved vaccination strategy for people previously immunized with BCG or to be immunized with BCG in the future. In effect, the improved vaccination strategy involves priming with BCG and boosting with a protein that is administered separately during a subsequent vaccination(s). The use of this prime-boost strategy dramatically enhances protective immunity in an animal model. Thus the improved strategy described here utilizes a booster protein in subsequent vaccinations to increase efficacy and prolong protection.

*Abstract: None

*Applications: The booster can be used to augment immunity against M. tuberculosis and other mycobacteria (e.g. M. avium, a cause of pneumonia in immunocompromised patients such as AIDS patients, and M. leprae, the agent of leprosy). The vaccine is administered via injection (intradermally, subcutaneously, etc.)

*IP Issue Date: Feb 28, 2012

*Principal Investigation: Name: Guenter Harth
Department:

Name: Marcus Horwitz
Department:

Name: Michael Tullius
Department:

附加資料: Patent Number: US7622107B2
Application Number: US2003595385A
Inventor: Horwitz, Marcus A. | Harth, Gunter
Priority Date: 16 Oct 2003
Priority Number: US7622107B2
Application Date: 13 Apr 2006
Publication Date: 24 Nov 2009
IPC Current: A01N006500 | A61K003900 | A61K003902 | A61K003904 | A61K003938 | C12N001500
US Class: 4240931 | 4241841
Assignee Applicant: The Regents of the University of California
Title: Recombinant intracellular pathogen immunogenic compositions and methods for use
Usefulness: Recombinant intracellular pathogen immunogenic compositions and methods for use
Summary: The immunogenic composition is useful in a vaccine strategy for inducing an immune response in host.
Novelty: New immunogenic composition comprising a recombinant BCG comprising extrachromosomal nucleic acid encoding Mycobacteria major extracellular proteins, useful in a vaccine strategy for inducing an immune response

主要類別: 生物醫學

細分類別: DNA /基因工程

申請號碼: 8124068

其他

State Of Development

The strategy of boosting BCG with a booster protein has been tested in vivo in the highly relevant and stringent guinea pig model of pulmonary tuberculosis.

Background

Tuberculosis (TB) remains one of the world's most important infectious diseases. The causative agent, Mycobacterium tuberculosis, is the leading cause of death of any infectious agent. Each year, approximately 8 million people develop active pulmonary TB and two million die from this disease. The World Health Organization (WHO) has declared TB a global health emergency, the first disease so designated. Compounding the problem, strains of M. tuberculosis resistant to the major antibiotics used to treat tuberculosis are rapidly emerging worldwide. This has given new urgency to the need to develop an effective prophylaxis for TB. Vaccination is particularly important for developing nations and at-risk populations.

Four billion people in the world have been vaccinated with the currently used vaccine, bacille Calmette-Guerin or BCG, and approximately 100 million additional individuals are vaccinated with BCG each year. Since BCG provides only partial immunity to tuberculosis, these people could benefit from a booster vaccine that enhances their level of protection against tuberculosis.

Related Materials

Additional Technologies by these Inventors

Tech ID/UC Case

21724/2004-046-0

Related Cases

2004-046-0

國家/地區: 美國

欲了解更多信息，請點擊這裡